Kereiakes DJ, et al. - Researchers pooled data from eight controlled (placebo/ezetimibe) phase 3 ODYSSEY trials to test alirocumab (a proprotein convertase subtilisin/kexin type 9 inhibitor) in terms of effectiveness and safety for treating patients with atherosclerotic cardiovascular disease (ASCVD), with or without prior coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]). The tested regimen was alirocumab 150 mg or 75 mg with possible dose increase to 150 mg (75/150 mg) every 2 weeks (Q2W) vs placebo, and alirocumab 75/150 mg Q2W vs ezetimibe. Low-density lipoprotein cholesterol, lipoprotein (a), non-high-density lipoprotein cholesterol, and apolipoprotein B levels were significantly reduced from baseline to week 24 (vs control) by alirocumab, regardless of stratified treatment group or revascularization status. With general good tolerability, alirocumab displayed efficacy with a similar safety profile in high-risk patients with or without prior revascularization.